Equities research analysts at Bank of America Corporation began coverage on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a research note issued on Friday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Several other equities research analysts also recently commented on NLNK. Zacks Investment Research downgraded NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Jefferies Group LLC reiterated a “hold” rating and issued a $7.00 price objective on shares of NewLink Genetics Corporation in a report on Friday, July 14th. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Friday, July 28th. ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $8.00 to $22.00 in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $26.60.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 11.25 on Friday. The stock’s market capitalization is $330.99 million. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The company has a 50 day moving average of $10.67 and a 200-day moving average of $11.52.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. Equities research analysts predict that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “NewLink Genetics Corporation (NLNK) Research Coverage Started at Bank of America Corporation” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/newlink-genetics-corporation-nlnk-research-coverage-started-at-bank-of-america-corporation.html.

In other news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of the business’s stock in a transaction on Friday, October 6th. The stock was acquired at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now directly owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 13.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. bought a new stake in shares of NewLink Genetics Corporation during the 1st quarter valued at about $297,000. Gotham Asset Management LLC bought a new stake in shares of NewLink Genetics Corporation during the 1st quarter valued at about $313,000. American International Group Inc. grew its stake in shares of NewLink Genetics Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 880 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of NewLink Genetics Corporation during the 2nd quarter valued at about $125,000. Finally, Advisor Group Inc. grew its stake in shares of NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 54.77% of the company’s stock.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.